CHRS News & Events

Reports Q4 revenue $12.75M, consensus $14.09M. "We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million," said Denny Lanfear, Coherus chairman and CEO. "We are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts."

Coherus Oncology announced a proposed underwritten public offering of its common stock. All of the shares in the offering are being offered by Coherus. Coherus intends to use the net proceeds from the proposed offering to support the ongoing commercialization of LOQTORZI, to continue clinical development of its product candidates, and for working capital and other general corporate purposes. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners for the proposed offering.